Domo signs strategic collaboration agreement with AWS for AI solutions
Chaim Indig, the Chief Executive Officer of Phreesia, Inc. (NYSE:PHR), a $1.4 billion healthcare software company showing strong revenue growth of ~18% and maintaining a GREAT financial health score according to InvestingPro, has recently sold a significant portion of his holdings in the company, according to a Form 4 filing with the Securities and Exchange Commission. The transactions, dated April 8, 2025, involved the sale of 12,167 shares of Phreesia's common stock at a weighted average price range of $23.00 to $24.915 per share, amounting to a total of $290,218.
The sales were conducted in multiple transactions, with 7,434 shares sold at a price averaging $23.4568 and another 4,733 shares sold at an average price of $24.475. These transactions were made as part of a non-discretionary sell-to-cover policy to address tax withholding obligations related to the settlement of restricted stock units.
Following these transactions, Indig retains direct ownership of 1,257,665 shares. Additionally, he holds indirect ownership of 255,000 shares through the Indig Dynasty Trust, managed by a family member.
Investors and analysts often closely monitor insider transactions like these to gauge the confidence levels of company executives in their firms' prospects.
In other recent news, Phreesia Inc . has been the focus of several analyst firms following its latest financial disclosures. Jefferies increased its price target for Phreesia from $28.00 to $32.00, maintaining a Buy rating, citing the company's fourth-quarter earnings and strategic shift towards Network Solutions as key factors. KeyBanc Capital Markets also reiterated an Overweight rating with a $30.00 price target, emphasizing Phreesia's significant margin improvements and its growth potential within Network Solutions. Similarly, Raymond (NSE:RYMD) James maintained an Outperform rating with a $30.00 target, highlighting the company's strategic focus on enhancing free cash flow as a positive development.
DA Davidson expressed continued confidence in Phreesia by reiterating a Buy rating and setting a $36.00 price target, noting that the company's fiscal year 2025 results met expectations. The firm believes Phreesia's stock is undervalued, trading at a lower EBITDA valuation than its peers. Across these analyses, there is a shared optimism about Phreesia's ability to leverage its business model for sustained growth and profitability. Each firm points to different aspects of Phreesia's strategy, from operational leverage to free cash flow generation, as reasons for their positive outlooks. These recent developments indicate a strong consensus among analysts about Phreesia's future potential in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.